INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. concerning allegations of securities fraud and unlawful business practices related to the company's investigational gene therapy for Danon disease [1][2]. Group 1: Lawsuit Details - The lawsuit involves claims that Rocket and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Rocket securities during the Class Period have until August 11, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Incident Background - On May 27, 2025, Rocket announced an unexpected Serious Adverse Event (SAE) involving a patient in the Phase 2 trial of RP-A501, which led to a clinical hold by the FDA [4]. - Following the announcement, Rocket's stock price dropped by $3.94 per share, or 62.84%, closing at $2.33 per share [4].